-Primary Objective: This is a first-in-human, open-label, Phase 1a/b master protocol to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of PF-07799544 (also known as ARRY-134) as a single agent and in combination with other targeted agents in participants with advanced solid tumors. PF-07799544 (also known as ARRY-134) is a highly selective brain-penetrant small molecule inhibitor of MEK1/2 that is being investigated in participants with advanced solid tumors. -Secondary Objective To characterize the single and multiple-dose PK of PF-07799544 as a single agent. To evaluate preliminary antitumor activity of PF-07799544 as a single agent.
What is the full name of this clinical trial?
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS